Revenue Is Not (Always) the Story

Let's begin by picturing three companies.

Company A, B, and C.

Company A has revenue growth of 18%.

EBITDA is up 15%.

And profit is up 10%.

That means the company is bigger, but slightly worse economics per rupee.

Then there's company B, where revenue is up 12%, EBITDA is up 20%, and profit is up 25%.

It's a similar size increase in ambition, but extracting much more from every incremental rupee spent.

Then there's company C, Revenue is up only 10%, but EBITDA is up 25%, earnings up 30%.

Why? Because the composition of the business changed underneath the top line.

This is what I find fascinating.

It's that these three are not different business models.

They are three points on the same dial.

The gap between revenue growth and EBITDA growth turned up by different amounts.

What makes Company C interesting isn't that it's a differentiated species.

It's that the gap is wide enough and durable enough that it stops being a margin story and starts looking like a strategy.

It becomes a strategy.

And that's the test we're going to apply all the way through.

Is the gap durable or is it one good quarter looking like a strategy? Revenue tells you where a company is going.

EBITDA, meanwhile, tells you if the model is improving, but earnings architecture tells you what the company is becoming.

And that's what's interesting to investors like us.

Markets don't ultimately pay for revenue.

They pay for the durability of future cash flow.

So the third lens is the one that matters the most and the one I've heard pharma speak the least about.

So let's look at the classification of these different companies.